LLWinter2016 (3)

Meet the 2016
Life Science Catalysts
10
14
30LifeLinesFor the California Life Science Community
Public Policy: New Frontiers,
New Challenges and Opportunities
Global Partnering Conferences:
What Drives Success?
Pilot Program Helps Student
Take Off
VOLUME 25, ISSUE 3 Wint er 2016

BRENT JACOBS
brent.jacobs@cushwake.com
CA License No. 791657
GREG BISCONTI
greg.bisconti@cushwake.com
TED JACOBS
ted.jacobs@cushwake.com
(858) 452-6500
ONE TEAM. ONE FOCUS.
www.sdlifesciences.com
REAL ESTATE
EXPERTS FOR THE
LIFE SCIENCES
INDUSTRY
LILLY
300,000 SF Tenant Representation
DEXCOM, INC.
ARCTURUS THERAPEUTICS
CRINETICS PHARMACEUTICALS
AMBRX
SYNTHETIC GENOMICS
BIOCOM
NITTO DENKO
AJINOMOTO ALTHEA

Greetings to our members throughout California, Japan and France and welcome to
our winter 2016 edition of LifeLines. As Biocom continues to grow across the state and
around the world, I want all of our members to know what we are doing to enhance our
efforts to deliver continued value across our broad spectrum of offerings. As I write this
column, our association stands at more than 800 members strong, with an expanded San
Diego headquarters facility, a newly opened office in Los Angeles staffed by a team of 5
professionals and additional staff in San Francisco, Washington DC and Sacramento. Our
team of 43 employees is already moving in an unprecedented manner to live up to our
reputation as California’s longest-established and largest life science association. And as I
write this column, I am returning from a week of successful partnering meetings between
our members and our strategic partners at EuroBioMed, the life science association in
France.
This issue’s cover story celebrates the winners of our inaugural Life Science Catalyst
Awards. These accomplished young entrepreneurs represent California’s finest contributors
to the growth of our life science sector. We salute them as the new generation of life science
business leaders. In a related story, you will meet one of our accomplished members,
Abreos Biosciences, which was named “hottest” device company in Southern California at
our annual DeviceFest Conference “Five in the Hotseat” competition. Finally, staying with
the theme of engagement with “entrepreneurs of the future”, you will hear from one of the
ILSE students who participated in the first year of this important new program.
Because our association is only as strong as the members who support us, we have
chosen to focus much of this issue on the diversity of our membership programs and the
broad engagement of our members. With rapid membership growth in the LA area, you will
read about the terrific work of the new new Biocom team in LA. Next, John Newsam of Tioga
Research contributes an article on the growth of one of our most active and largest sectors,
the CRO group. Most of our members participate in and enjoy the enormous benefits of
the Biocom Purchasing Group, which recently welcomed Thermo Fisher Scientific to the
program as our exclusive and exciting new provider of laboratory supplies and services.
Finally, as a measure of the success of our health care benefits contract, you will find
important information about the reduced premiums under our Health Care Benefits Trust.
At the core of Biocom is our long-standing work in public policy and advocacy at the
regional, state and federal levels. It has been a very busy and challenging 2016 for us in
each of these arenas. In this edition we discuss how our talented team of policy professionals
continues to fight to ensure that the unified voice of our California life science sector is
clearly heard in the face of initiatives to control pricing and increase regulation.
Over the next five years, we have chosen to strategically focus on ensuring that we
lead the effort to make Southern California the leader in personalized medicine, through
partnerships between our members and with researchers, investors, and other collaborators.
Four stories focused on these topics round out this edition: in the research arena you
will read about the 50-hour genome, as accomplished by Dr. Steve Kingsmore of the
Rady Children’s Hospital Institute for Genomic Medicine, and a Q&A with UC San Diego
Associate Vice Chancellor for Innovation and Commercialization Paul Roben on working
more closely with our community to bring innovative ideas to market. Next, you will find
two articles that reflect important pillars of Biocom: capital development and partnering.
Biocom has a variety of capital development programs that are explained in detail. Last,
you will get an insider’s view of our upcoming 7th Annual Global Partnering Conference
with a guest article by planning committee co-chair Mark Wiggins.
2 Cover Story: Meet the 2016 Life Science
Catalysts
10 Public Policy: New Frontiers, New Challenges
and Opportunities
13 Guest: One CRO’s Success Story: a Foundation
for Growth
14 Guest: Global Partnering Conferences: What
Drives Success?
16 Q&A with Paul Roben, Associate Vice Chancellor
for Innovation and Commercialization, Office of
Research Affairs, UC San Diego
17 Biocom LA: Biocom’s Los Angeles Office:
A Warm Welcome
18 Capital Development: Capital Development
Landscape: Southern California’s Life Science
Industry
20 Biocom in the News: Biocom’s Making Headlines
21 Members in Action: Super Angel Day
22 STEM In The Community – The Future Is Now In
Pediatric Genomics!
25 Members in Action: Biocom’s 9th Annual
DeviceFest Conference: Congrats to Abreos
Biosciences
26 Members in Action: Breakfast Meeting on
Emerging Diseases, Including Zika
29 Members in Action: Biocom PAC Annual Elected
Officials & Candidates Reception
30 Biocom Institute: Pilot Program Helps Student
Take Off
32 Purchasing Group: Accelerating Growth
& Changing the Game
34 Meet the Biocom Team
38 Biocom Board of Directors and Committee
Leadership
39 Biocom Membership
WELCOME
I N T H I S I S S U E By Joe Panetta,
President and CEO, Biocom
WWW.BIOCOM.ORG
EDITOR: Jennifer Landress
COPY EDITOR: Julie Ames
DESIGN & LAYOUT: Cathy Tran
V O L U M E 2 5 , I S S U E 3
Biocom LifeLines Winter 2016 1

40
U
N
D
E
R
AN EPIC ENTREPRENEUR
Dena Marrinucci, 34 | VP of Research, SalveoDx
Dena Marrinucci’s latest biotech startup is still very much in stealth mode. But if
the success of her last big idea is any indication, we can expect it to be nothing short
of Epic. While earning her Ph.D. at The Scripps Research Institute, Marrinucci became
captivated by the potential of better cancer diagnostics—and by what that can mean for
patient health. Finding dangerous cells earlier: Marrinucci devoted years of academic
research to a technology that could detect cancer cells circulating in the blood stream,
allowing earlier disease intervention. Based on her findings, she co-founded San Diego-
based Epic Sciences, where she served as chief scientific officer and forged dozens of
collaborations with top pharma and biotech companies such as Genentech and Pfizer.
The big reveal: Marrinucci, who reached the summit of Mount Kilimanjaro five years ago,
is now plotting her next adventure: A consumer-facing diagnostics startup, SalveoDx,
which already has seed funding from Domain Associates.
COVER STORY By Kelly Quigley and Lauren Fish,Canale Communications
In the world of science, a catalyst is a substance that increases
the rate of a chemical reaction. In everyday life, it refers to people
or events that spark action.
Each of the 10 winners of Biocom’s inaugural Life Science
Catalyst Awards can arguably meet both definitions. They’re not
only defining the unique chemistry of San Diego’s life sciences
scene—bringing a fresh mix of energy, ideas and ambition—but
they’re also sparking meaningful change to human health through
their research and entrepreneurship.
And they’re all doing it before they turn 40.
Presented in conjunction with the San Diego Venture Group,
Biocom’s Catalyst Awards honor the up-and-coming scientists,
executives and business advisors who are shaping the future of life
science in America’s Finest City.
“San Diego’s life science community is continually evolving to
meet the needs of the world around us, from our global leadership
in genomics to our innovative work in cancer diagnostics and
therapeutics,” said Jennifer Landress, senior vice president and
chief operating officer of Biocom. “These winners represent the
many facets of our dynamic industry and give us great excitement
for what lies ahead in San Diego.”
Catalyst Award nominees were evaluated by a committee
of executives and board members from both Biocom and the
San Diego Venture Group, which took great effort to narrow an
impressive list to just 10 recipients. They looked for people who
are not just excelling in their life science-focused profession, but
are also going above and beyond to invigorate the sector and bring
industry collaboration to a new level.
Meet the 2016 Life Science Catalysts
2 Biocom LifeLines Winter 2016

INSURING BIOTECH SUCCESS
Mike Milligan, 38 | Principal, Leader of the Life Science Practice, Barney & Barney
Insurance is a business necessity in almost any industry, but especially so in the risk-
taking realm of biotech and pharma. And if there’s anyone in San Diego who is an expert
in this niche area, it’s Mike Milligan. Back in 2000, Milligan was attending a Biocom event
when he heard a patient—a mother—share her story of cancer survival. The story hit
close to home, as Milligan’s father had cancer many years earlier. The experience sparked
Milligan’s passion for making sure biotech companies have the insurance they need to
continue developing life-saving medicines. Making it big: In the following years, Milligan
helped expand Barney & Barney’s life sciences practice into the company’s largest, today
serving more than 500 life science clients—including 150 public companies. He’s helped
insure hundreds of clinical trials in the U.S. and abroad, and helps biotech execs wade
through a range of other risky business issues. Living the dream: The dad of three loves
San Diego’s small-town feel, which is why he says he’d never want to leave.
THE LAWS OF LIFE SCIENCE
Ed Truitt, 34 | Co-Founder and CEO, Lubris Biopharma LLC
It’s not common to see a corporate attorney starting up new biopharma companies.
But Ed Truitt’s not your common guy. After receiving his law degree from University of San
Diego, Truitt focused for several years on patent litigation and startups before deciding to
launch his own company focused on early detection of cancer. He’s since launched another
company that’s developing therapies for eye conditions. Both are based on science from
UCSD. Poking holes: Truitt says that law is a lot like science; in both fields your goal is
to build solid evidence to prove that something (your argument or your hypothesis) is
unequivocally true. Working in biotech now, Truitt says he deals with lawyers more so
than ever. Engaging the entrepreneurs: In 2006, Truitt helped his wife, Nikki, create the
Entrepreneur Challenge at UCSD, and continues to be passionate about helping young
leaders pursue their business goals.
THE MICROBIOME MAGNATE
Rob Knight, 39 | Faculty Director, Center for Microbiome Innovation
University of California, San Diego
UC San Diego’s School of Medicine made a pivotal hire in 2015, winning out over elite
universities around the country when they brought on board Rob Knight, Ph.D., a superstar
biologist. Knight is recognized globally for his expertise in all things microbiome—the
next frontier of medicine. While San Diego’s hiking and scuba diving scene didn’t hurt,
Knight was lured by the city’s rich ecosystem of sequencing companies (Illumina, Synthetic
Genomics) and scientific research institutions, which together can accelerate research
into patient care. A voice in D.C.: Knight was a driving force behind the White House’s
$121 million National Microbiome Initiative, launched in early 2016, of which UCSD is
now a key participant. All about the data: Always one to want to know more about the
many microbes that make us who we are, Knight has been collecting his own poop for
sequencing essentially every day for the last eight years (and he’s not shy about it).
COVER STORY

MHM (Mayer Hoffman McCann P.C.) is an independent CPA firm that is a member of Kreston Internaaonal, Limited, a global network of independent accounnng firms.
www.mhmcpa.com | 858.795.2000
Contact David Diamond
Technology & Life Sciences Praccce Leader
ddiamond@cbiz.com
We are one of the leading providers of accounnng services to
Southern California’s Technology & Life Sciences industries - focusing on
private companies preparing to go public or be acquired.
Providing aaest services to a wide variety of
public companies, early-stage and growing private companies.
[Experience How Everything We Do
Has A Single Focus - Your Success]

COVER STORY
DECODING BIG PROBLEMS
Ashley VanZeeland, 34 | Chief Technology Officer, Human Longevity Inc.
Ashley VanZeeland knows how to make things happen, whether she’s in the lab or the
boardroom. From identifying potential genetic factors of autism, to forging public-private
partnerships that speed drug development, her accomplishments often reflect her dual
background in business (she holds an MBA from UCSD) and her Ph.D. in neuroscience.
Tech meets genes: VanZeeland, who once headed up strategic partnerships for Scripps
Genomic Medicine, co-founded Cypher Genomics with leading scientists from Scripps—
including Dr. Eric Topol—to provide large-scale cloud solutions to genomic problems.
Cypher was bought by Human Longevity Inc., where she is now chief technology officer and
head of pediatrics. Elegant approach: The yoga enthusiast, surfer and new mom was set
on becoming a professional ballerina until she injured her ankle in a car accident. While
she still wonders what life would have been like if she pursued dance, it’s unlikely she
would have made such an immense impact on human health.
KING OF CHEMISTRY
Phil Baran, 38 | Professor, Darlene Shiley Chair in Chemistry, The Scripps Research Institute
With a Ph.D. in hand at 24, and tenure at The Scripps Research Institute at age 28, you
can only imagine what the uber-achieving organic chemist Phil Baran has accomplished before
turning 40. Baran, the Darlene Shiley Chair in Chemistry at TSRI, still spends plenty of time
in the lab, where he continuously breaks new ground in natural product synthesis. But he
also keeps busy consulting with biopharmaceutical giants such as Bristol-Myers Squibb and
AstraZeneca, and serving as “sultan of synthesis” for Sirenas Marine Discovery, a San Diego
biotechnology company that’s developing new drugs inspired by marine life. Cream of the crop:
Baran was recently named a 2016 Blavatnik National Laureate, an honor that comes with the
largest unrestricted cash award ($250,000) given to early-stage scientists. Inspired by the sea:
Baran’s favorite molecule is Palau’amine, an alkaloid found in certain sea sponges off of the
coast of Palau, the compound’s namesake.
WATERING THE SEEDS
Susie Harborth, 37 | General Partner and CFO, BioInnovation Capital
Managing Director and Co-Founder, BioLabs San Diego
Susie Harborth knows all the secret ingredients required to keep new biotech businesses
humming. While serving as the general partner and chief financial officer at Boston-area
venture firm BioInnovation Capital, Harborth simultaneously co-founded BioLabs San
Diego, a brand new business incubator that provides state-of-the-art lab space, equipment
and a host of other resources for emerging life science companies. Her goal is to remove
those earlier barriers to success. Fostering innovation: Harborth, who has a master’s
in biology from Harvard, also sits on the Advisory Board at LabCentral, a nonprofit that
provides co-working spaces to start-up biotech companies in Massachusetts. Globe
trotter: She’s traveled the world and spent time in other big biotech cities, but Harborth
has happily settled back in her hometown of San Diego, where she’s set on making sure
promising life science startups have the support they need to grow.

COVER STORY
LIGHTING THE WAY
Martyn Gross, 33 | Founder, Vice President of Innovation, Clarify Medical
Martyn Gross is the founder of a startup medical device company that’s seeking to use
portable light as an affordable prescription therapy for patients with psoriasis, eczema and
other skin conditions. Gross, a psoriasis patient himself, can speak personally to the need
for a treatment that allows patients to treat their conditions at home instead of visiting
doctors or clinics several times a week. Passion pays off: Clarify Medical has been named
San Diego Venture Group Cool Company, Biocom DeviceFest’s coolest Device and Xconomy’s
2017 San Diego Tech Startups to watch. In 2016, Gross also received the Our City San Diego
magazine’s recognition as the Most Influential Innovator. His other passion is microfinance.
He’s made trips to Uganda, Rwanda, Dominican Republic, Nepal and India to assist non-
governmental organizations. Nothing like nature: Gross says that hiking, rock climbing and
surfing have given him the mental focus to make some of his smartest business decisions.
DNA MATCHMAKER
Michael Heltzen, 36 | Co-Founder and CEO, AllSeq
Serial entrepreneur Michael Heltzen has created the first “marketplace” for DNA sequencing
services, providing researchers with a robust, online bank of services and resources to
help them get their projects done quickly and well. Formerly of Denmark, Heltzen chose
San Diego for his new venture because he says the city has the best talent and resources
in the world to support genomics. His company, AllSeq, is seeking to drive the genomics
revolution into everyday use by making services accessible. Outspoken advocate: Heltzen is
known as a genomics industry cheerleader, investor and visionary, recently participating in
many key sessions at the Festival of Genomics in San Diego. A close call: When living in the
Philippines in the early 2000s, Heltzen was nearly killed by a highly toxic stonefish, only to
be saved by an antidote that the tiny, local hospital had at the ready.
A HEALTHCARE VISIONARY
Tony Grover, 39 | Vice President, Business Development, Banyan Biomarkers Inc.
After helping to establish a medical clinic at a Bangladesh orphanage, and
witnessing the disparities in the health care industry, Tony Grover vowed he would
make a difference in improving the lives of others. Now at Banyan Biomarkers, a
company that develops rapid blood tests to diagnose time-sensitive concussions
and traumatic brain injuries, he’s living up to his promise. Grover is also active
with the American Association of Clinical Chemistry and the American Academy of
Neurology, where he served on the Corporate Roundtable Executive Committee.
Biotech hub migrant: Grover, who’s been a resident of all three top U.S. biotech
clusters, says he views San Diego as the most collaborative of all—it’s a quality
that promotes innovation and speeds time to market. He’s a fighter: In his free time,
Grover enjoys teaching his daughters Brazilian jiu-jitsu.

Honorable Mentions
COVER STORY
Looking for an assay development partner?
Francie Barron, Ph.D., 36
Vice President of Biology,
Regulatory Affairs
Nanomedical Diagnostics
Sanjeev Bhavnani, M.D., 39
Physician-Investigator
Scripps Clinic and Research
Institute
Brendan Eckelman, Ph.D., 37
Founder and Vice President,
Scientific Operations
Inhibrx
Thomas Hitchcock, Ph.D.,
38
Founder and CEO
Xycrobe Therapeutics

Jonathan Kabakoff, 31
Senior Principal, Science
& Technology
Alexandria Venture
Investments/Alexandria
Real Estate Equities
Ryan Taft, Ph.D., 38
Senior Director, Scientific
Research
Illumina
Prashant Mali, Ph.D., 36
Assistant Professor of
Bioengineering
University of California,
San Diego
Dina Uzri, Ph.D., 34
R&D and Business Development
Abreos Biosciences
David Puerta, Ph.D., 37
Chief Operating Officer,
Vice President of Discovery
Forge Therapeutics
Biocom Catalyst Award winners
mingling with biotech leaders at
the San Diego Venture Group’s
Life Science Luminary Dinner
held at the home of Magda
Maquette and Francois Ferre.
Travis Stiles, Ph.D., 30
CEO
Novoron Bioscience
For more information on the Biocom Catalyst Award winners and honorable mentions, please visit www.biocom.org/s/Catalyst-Awards.
COVER STORY

Congress and the California Legislature have both adjourned,
and although Congress will convene for a “lame duck” session
after the election but before the new Congress is sworn in, much of
their work is done for the year. 
2016 has been a year during which the industry has been under
constant scrutiny in the policy arena, much of it coming to a head
in the past few months.  Whether it is the entire industry being
unfairly painted with a broad brush because of the actions of a few
individual outliers; having blame shifted upon it by other aspects
of the health care delivery system in expensive, well-orchestrated
campaigns; or legitimate policy discussions trying to manage the
intersection of the costs of innovative new cures and delivering
the highest therapeutic value to the patient based on probable
outcomes, the core model of proportionate return for very high risk
has been threatened.
Congress returned from a seven-week recess on September 6
with a long list of unfinished business, including passing a final
21st Century Cures bill. Despite the efforts of House Energy &
Commerce Committee Chair Fred Upton to bring the bill to the
floor in September, the bill is not likely to move forward until after
the November 8 election. 
The House measure contained almost $10 billion in mandatory
funding for the National Institutes of Health (NIH) but since its
passage last year, the original offsets have been used to fund other
bills and are no longer available, which has delayed the conference
process. Mandatory funding for the NIH is a prerequisite for
Democrats in both Chambers to continue to support any 21st
Century Cures package.  
Biocom has been very supportive of the initiative and continues
to advocate for the inclusion of mandatory funding for the NIH and
other regulatory and reimbursement provisions, while lobbying to
ensure that legislators stay away from offsets that could harm our
industry, such as modifications to FDA’s Approved Risk Evaluation
and Mitigation Strategies (REMS) system.
In the State Legislature, the country watched as Senate Bill
(SB) 1010 unfolded.  This bill would have required companies
to provide a wealth of pricing information to the state for public
release.  The version passed by the Assembly Health Committee,
for instance, required drug manufacturers to give health plans and
other purchasers 30 day advance notification of price increases
exceeding 10 percent or $10,000 (over a 12 month period).
Biocom played a critical role in a large coalition of patient groups,
life science trade associations (BIO, CLSA and PhRMA in particular),
and companies to educate Assembly Appropriations Committee
members on the possible unintended market consequences of the
bill as passed by the Assembly Health Committee.  Due in part
to these efforts, the Assembly Appropriations Committee made
significant changes to the bill before passing it to the Assembly
floor.  Among these amendments was a change to a 25 percent
threshold for reporting price increases and a one-year delay (to
January 1, 2018) in implementation of this first in the nation
reporting system. 
On August 17, as a result of the changes mentioned above, the
bill’s author, Senator Ed Hernandez, announced he would not be
attempting to move this particular bill forward, but instead would
seek legislation next year.   
If it seems like 2017 will be a very busy year in the policy
world, it will be.  Both presidential nominees have regularly
espoused rhetoric critical of the industry on the campaign trail. 
The California Legislature will have a number of new members
unfamiliar with the critical role the industry plays in the state’s
economy.  Biocom is preparing to take on these challenges.  We
are already engaged with many of our Los Angeles stakeholders,
including offices of local elected officials, to evaluate local policy
needs, prioritize them, and begin effecting change there at the
local level.  In many ways, as Biocom moves forward, we are doing
so by getting back to our roots of driving policy change through
industry coalition building. 
Biocom is expanding its policy outreach efforts, including
developing engagement tools for our members, and will continue
to consult with our members on how we can best communicate the
industry’s message to policy makers.   We are developing deeper
relationships with Los Angeles legislators through our new office
there, enlisting them as partners in developing the kinds of jobs
and industry recognition and cohesion in Los Angeles that their
neighbors in San Diego and San Francisco already enjoy.  As
Biocom’s membership continues to grow and progress, we will
continue to serve the policy needs of our expanding universe.  
Jimmy Jackson is the Senior Vice President
of Public Policy for Biocom. He oversees
government affairs and public policy for the
organization.
PUBLIC
POLICY
New Frontiers, New Challenges and Opportunities
By Jimmy Jackson,
Senior Vice President of Public Policy, Biocom

Over the past two months many people have asked how a
Contract Research Organization (CRO) came to be listed as one
of 2016’s most exciting, early phase companies in North America.
130 companies presented to peers and judges at the final stage
for the RedHerring100 recognition; only six were life sciences
companies, and just one was a CRO.
The answer to the frequent question, is complex. Like many
outstanding companies, we have an impressive team with a robust
and lengthy track record. We are delighted by the level of our
engagement with our clients, both in industry and academia, and
we are pleased with our business model and growth trajectory.
But I have come to realize that the RedHerring100 award
recognizes much more than Tioga Research. It is also a reflection
of San Diego’s life science ecosystem.
As a CRO we have a specific focus. We work only on formulations
applied topically, that is to the skin or mucosa. When discussing
skin-applied products we distinguish between four types of delivery:
superficial (exterior surface only), topical (into the skin to treat, for
example, a dermatological condition), regional (through the skin
but concentrating in proximal tissue or joint), and transdermal (for
systemic availability). We address each of these scenarios and we
count among our clients cosmetic and skin care companies, even
if our main focus is pharmaceuticals. We serve as a pre-IND CRO,
supporting clients variously from product concept assessment
through pre-clinical development.
The bulk of our work is on formulation innovation and screening
the delivery of an active from a formulation into and through the
skin. Unlike typical oral or injectable formulations, the extent
of delivery of an active from a skin-applied formulation can vary
hugely, with even subtle changes in formulation composition. Such
changes are today not predictable and formulation compositions
that work well for one active typically perform sub-optimally for
another active. Historically, selection of a topical formulation
commenced with a handful of ‘off-the-shelf’ vehicles into which
the drug would be introduced, perhaps at different strengths.
The formulation in this small set that performs best would likely
be chosen for development. Today, though, much of the value of
Tioga Research’s capabilities and proprietary technologies derives
from our ability to discover optimally-performing formulations
by preparing and screening many tens or hundreds of distinct
compositions.
This simple overview underscores that are we are not only
specialized, but that we also address only one phase of the
full research and development cycle. Being able to cooperate
effectively with other local organizations with complementary skills
is therefore important, both to us and to our clients. The April
2016 Biocom CRO Education Series Event “Skin-applied Products
– from Concept to Approvals in San Diego” included presentations
from two complementary companies, Pharmatek Laboratories and
Therapeutics Incorporated, with which we are proud to interact.
It also featured Pieter Dorrestein, a UCSD professor and global
expert in the emerging skin microbiome field. Links with our
academic research institutions can be important, and the state-of-
the-art instrumentation accessible at their core facilities can also
prove invaluable.
Southern California is home to a constellation of CROs and
Contract Manufacturing Organizations (CMOs) that can have global
appeal. Tioga Research already has clients in India and Japan and
we look soon to adding clients in China. Our region also has a notable
history and a very substantial presence in skin interests generally.
Clinical dermatology, esthetic dermatology, skin culture, wearable
devices, hair growth, skin imaging and diagnostics, tattoos, skin-
and hair-related genomics are some well-recognizable examples.
Local leaders from across these interest areas are now working to
establish a Skin Interests Locus community and to better promote
the strengths of our region in this area.
Southern California is envied for the effectiveness of the
communities it establishes. It is rightly stated that those working
to advance today’s science and technologies are standing on
the shoulders of giants. As I often remark when introducing the
San Diego Skin Interests locus in other regions, not only is Tioga
Research standing on the shoulders of giants, but we are also
rubbing shoulders with future giants.
John Newsam is CEO of Tioga Research, Inc.
and is a Biocom CRO committee member.
GUEST
One CRO’s Success Story: a Foundation for Growth
By John M Newsam,
CEO,Tioga Research, Inc.

The best partnering conferences stimulate conversations and
collaborations that spill out into the halls, stretch far into the
dinner hour, and have attendees meeting for sunrise coffee to
continue discussions. Earlier this year, the large group filling
The Lodge at Torrey Pines ballroom had a world-famous, ocean-
view golf course within sight. However one could immediately
tell this group was here for a distinctly different purpose. The
standing room-only crowd was listening with tremendous interest
to a lecture by Dr. Patrick Soon-Shiong, named one of the Top 25
Most Influential People in Biopharma in 2015. He was describing
the U.S. Government-sponsored Cancer Moon Shot project and
his leadership role. While this was the most popular presentation
at the 2016 Biocom Annual Global Life Science Partnering
Conference (GLSPC) the conference consistently attracts other
remarkably accomplished keynote speakers and panelists.
As a member of the small planning committee who helped start
this conference seven years ago, I’ll share that our vision was to
bring the business and corporate development industry movers and
shakers from around the world to Southern California to witness
what’s happening in our important life sciences hub and annually
discuss this landscape on a global basis. No such meeting existed
seven years ago. Today, the mission is largely unchanged, but the
quality of the 200 attendees and speakers is extraordinary. And
the event continues to attract top-notch speakers and participants.
The primary goal of the GLSPC is to bring together senior level
life science industry leaders keen to form corporate partnerships
especially between a pharmaceutical company and a biotech or
start-up company. The types of partnerships being contemplated
at this conference are surprisingly comprehensive and include
licensing arrangements, mergers and acquisitions and even
investments by venture capital funds.
While there are partnering conferences around the country,
Biocom’s GLSPC is unique. This is the only conference of its type in
Southern California. And with the venue for the past several years
at The Lodge at Torrey Pines, we leverage the delightful setting to
create a one-of-a-kind San Diego vibe. We believe the venue helps
contribute to the casual nature of the networking and fosters open
and transparent interactions. It comes as no surprise when surveys
show that the conference has an impressive repeat attendance
rate. Why is that? One reason is because this conference smoothly
blends so many different forums for collaborating, learning
and spontaneously discovering new partnership opportunities.
Here’s a sample of the diverse activities that take place:
• Individual company presentations from over 20 exciting
start-ups
• Keynote presentations
• Fireside chats
• Panel presentations from senior-level members of the industry
• 1:1 partnering meetings scheduled in advance via an online
meeting tool
• Planned breaks to allow for informal networking
The upcoming meeting will be held March 1 & 2, 2017 at The
Lodge at Torrey Pines. As a preview, here two examples of speakers:
• Keynote presented by Rupert Vessey, Executive Vice President
and President of Global Research and Early Development at
Celgene
• Fireside chat with George Golumbeski, EVP Business
Development & Planning at Celgene interviewed by Ed
Saltzman who is President of Defined Health
While the planning committee is putting the final touches on
the upcoming program, registration is now open along with the
application process for company presentations. I look forward to
seeing you there.
Visit Biocom’s Global Life Science Partnering Conference
website for additional information and registration:
www.biocomglobalpartnering.org
Mark Wiggins is a Senior Biotech Executive
and serves as a founding committee
member for the Biocom Global Partnering
Conference.
GUEST
Global Partnering Conferences: What Drives
Success?
By MarkWiggins,
Senior Biotech Executive
www.BiocomGlobalPartnering.org
March 1-2, 2017
The Lodge at Torrey Pines

Representing San Diego’s most notable bio-tech,
pharma and life sciences companies is a role
we take seriously. As the leading provider of
commercial real estate services in the San Diego
market and around the world, we are committed
to harnessing our unmatched real estate services
platform to deliver exceptional outcomes that
build competitive advantage for everyone
we serve.
Build on
Advantage
cbre.com/sandiego-occupier
@cbresandiego
THE LIFE SCIENCES
ADVANTAGE

Paul Roben, the new Associate Vice Chancellor for Innovation
and Commercialization (OIC) at UC San Diego, intends to “drive
innovation across all areas of campus, and to speed university
innovations to markets in California, the nation, and the world.”
Roben, who has combined the offices of technology transfer,
intellectual property, innovative design, and industry partnering
under the OIC roof, answers some questions about the new office,
the university’s goals, and the prospects for strengthening the
university’s “culture of innovation” to broaden the benefits for
both the campus and the regional community.
Q: How do you define innovation?
Roben: I define innovation as people with diverse ideas coming
together to create new solutions to the problems that we will all
face as a society over the coming years.
Q: How has your experience in economic development and
technology-growth shaped your approach to the mission of the
Office of Innovation and Commercialization?
Roben: I have worked in academia, in companies, and for a
government, so I have seen innovation at work from all angles.
This has shown me that innovation is, at its heart, all about
people. Fundamentally, my job is to provide as many opportunities
as possible for people from these different backgrounds to come
together with their diverse ideas, and to create the solutions of the
future. My office can then help to provide them with the education,
tools and resources necessary so they can make their ideas become
reality.
Q: The campus has a number of offices and organizations dedicated
to entrepreneurism and business-creation already. How does the
OIC fit into that existing framework?
Roben: The OIC is a cross-campus innovation platform designed
to ensure UC San Diego’s position as a major driver of regional
development. As you point out, there are many excellent
organizations and resources across campus doing outstanding
work in the innovation space. The OIC aims to bring the campus
to the next level by supporting and aligning those resources toward
the common goal of social and economic development. We are also
providing new resources in support of these organizations: People
development -- inspiring and motivating people to unlock their
inner creativity -- and innovation programs, such as Entrepreneurs-
in-Residence, Open-Flow Innovation Licensing, and Proof-of-
Concept funding. These programs will create those opportunities
where diverse people can come together and innovate.
Q: Given UC San Diego’s notable success in start-ups, and their
contributions to regional economic growth, how does the university
do even better in those areas?
Roben: One important role for OIC is to remove any barriers to
getting promising technologies into the hands of the people who
can develop them and start new companies. Our new Open-Flow
Innovation program makes it considerably easier for entrepreneurs
to create more new companies and jobs in the region.
Q: Can you elaborate on what the OIC is doing to bring ideas to
market faster?
Roben: In addition to Open-Flow Innovation, we are also launching
a number of initiatives, such as an Entrepreneur-in-Residence
program, to bring the expertise of the private sector to campus
and to help our innovators develop products and services faster.
These programs, together with initiatives in education, “innovation
concierge” services, and technology-development funding, are all
designed to bring ideas to market faster.
Q: What kind of response to your aggressive business-partnership
and business-development goals have you received from local
industry and community leaders?
Roben: Local leaders have been very supportive of this approach.
Most people acknowledge that the way to bring the entire region to
the next level of success is to work together to tackle the problems
facing society, and also to work together to build the reputation of
this region as one of the most innovative in the world, in order to
attract the best people and investment to the region. Local leaders
recognize UC San Diego as one of the major sources of people and
technologies that will drive these efforts, and welcome the chance
to partner with the university in our new business-friendly approach.
Q: Say I’m a student, or faculty member, or even a member of the
community looking for some expert help developing a new idea or
useful new tool. How does your new office, the OIC, help me?
Roben: One of the first things we are creating is an “entrepreneur’s
road map”-- basically a guide for anyone interested in this space
to help them find the resources they need to get to the next step
in developing their idea -- anything from mentorship to physical
space to legal services to investment. In the meantime, anyone can
contact my office and we will try and get them the help they need.
Q: You’ve put together a talented, experienced, and optimistic
team. Tell us what you and your team hope to have accomplished
in five years.
Roben: In five years, UC San Diego will be recognized globally as
the partner of choice for innovation.
Q &A
Q&A with Paul Roben,Associate Vice Chancellor for Innovation
and Commercialization, Office of Research Affairs, UC San Diego

Biocom opened the doors of its new Los Angeles office in June,
2016. Since then, we have seen excitement build over our arrival
and our efforts to showcase the exciting life science industry in
the greater LA area (more than 450 companies!). We believe in
the tremendous opportunity represented by this industry in LA and
have started to lay the groundwork to link everyone already in the
ecosystem.
By August, Biocom’s Los Angeles office was fully staffed and
operational and we hit the ground running. Using our 20-year
history of cluster-building, we work daily to advance our mission
to accelerate life science success in specific and meaningful
ways for our members. The new hires bring the Los Angeles office
staff total to five and include staff focused on advocacy, program
management, membership and our best-in-class purchasing group.
In addition to strategic hires, the LA office has been focused
on creating strong partnerships throughout the ecosystem. We
are partnering with the LA Economic Development Corporation to
respond to the LA County Board of Supervisors need for leadership
in pulling together stakeholders from across the industry, the
public sector and academics to catapult our life science cluster
onto the world stage. This requires that we work to attract more
capital to the region and to find ways to keep more of the great
companies that are spawned here local. These are among some of
our initial programming efforts and we are fortunate to work with
such engaged partners.
A big part of that effort requires us to tell our success stories to
the world. We are partnering with the local universities, research
institutes and their startups to raise awareness. Did you know that
each year UCLA spins out more startup companies than any other
UC campus, the majority in life science related fields? Last fiscal
year, they spun out 25 new startups, almost twice the next most
active campus (UC San Diego, with 15) and almost 30% of the
total startups spun out by the UC System as a whole!
Biocom’s LA office is also partnering with other local associations
to put on events and programming that will connect and grow the
industry. The LA Venture Association (LAVA) and the Biotech
Connection LA (BCLA) are just two of these – LAVA educates and
connects entrepreneurs within the local entrepreneurial ecosystem
and BCLA is a group founded by USC and UCLA grad students
whose mission is to facilitate the connection between academics
and the LA biotech industry to move innovation forward.
We have also been reaching out to the LA area’s elected officials
to look for ways for us to partner with them to grow and support the
industry in LA. Biocom’s CEO, Joe Panetta, and I spent a couple
of days this summer in Sacramento, speaking with members of
the LA delegation. In addition to working with companies in their
districts, we are looking for ways to partner on STEM education
and workforce development efforts.
Read more about our new hires and our upcoming events on the
LA office’s website at www.biocominla.org and follow us on twitter
at @BiocominLA for the latest updates on the LA area.
Dina Lozofsky is the Executive Director of
the Biocom Los Angeles office.
BIOCOM
L.A.
Biocom’s Los Angeles Office: A Warm Welcome
By Dina Lozofsky,
Executive Director, Biocom LA

California is known as a world-class life science industry leader
with a rich history of breakthroughs and milestones. Reflecting
back, many recall Genentech as the first official biotechnology
company. It was the first to successfully genetically engineer
human insulin using recombinant DNA technology in a laboratory
in 1978, and held the first biotech initial public offering on October
14, 1980. Since then, the state has burst onto the national scene
with countless life-saving products.
Taking a closer look, Southern California has come a long way
from its inception and is now one of world’s largest life science
hubs. Southern California rests on a foundation of scientific
training and prowess. It employs over 139,000 people in five
sectors: biopharmaceuticals, medical devices and diagnostics,
research and lab services, industrial biotechnology and biofuels,
and life science trade. The industry in California alone generates
$258 billion in economic activity. Economic activity in the life
science industry comes in many forms: investing direct dollars,
company collaborations, and mergers and acquisitions, all of
which can lead to future ROIs and create growth.
Contract Research Organizations
One example of future potential economic returns are Clinical
Research Organizations (CROs). CROs are crucial to a thriving life
science industry. They enable pharmaceutical, biotechnology, and
medical device industries to outsource research services for faster
discovery and clinical development of new products. Southern
California is home to the highest concentration of CROs in the
world. With more than 85 CROs, the region is in a class by itself.
Analysts predict a 10% annual increase for the CRO industry,
which may lead to advances in product pipelines and stimulate
additional regional capital growth.
Venture Funding
A more direct method of cultivating economic activity is deal-
making through venture funds. According to PricewaterhouseCooper
(PWC) and the National Venture Capital Association (NVCA), in
FY2015, $1.04B on 80 deals was invested through venture funds
in Southern California, specifically in biotechnology and medical
device and equipment companies, Although 2015 saw a decrease
in the number of total deals over the last couple of years, 80 deals
in FY 2015 versus 92 in FY2013, the Southern California region
saw a 12% increase in direct-dollars invested, leading to growth
in average dollars per deal. In FY2016, Southern California is on
pace to surpass FY2015, having already raised 64% of the total
invested dollars in just the first two quarters.
NIH Funding
In addition to millions invested through venture funds, there is
an equally important influx of money coming to Southern California
institutions and companies from the National Institutes of Health
(NIH). The NIH invests over $30B annually to help fund medical
research in the United States. In FY2015, Southern California
alone received approximately $1.75B in total annual funding from
the NIH.
Biocom’s Contribution
Although there are many funding sources available, the
environment for raising capital to fund life science companies
continues to be increasingly difficult. Capital is available for those
who can demonstrate they have the knowledge, expertise, team
and vision to meet today’s rigorous investment criteria. Biocom
is cognizant that life science companies need increased access
to capital, therefore Biocom will continue to offer programs that
assist member companies in accessing financing resources.
Working on behalf of more than 800 members, Biocom is the
largest, most experienced leader and advocate for California’s
life science sector. Through the efforts of Biocom and its Capital
Development Committee, companies have the opportunity to
showcase their products and ideas to potential investors. From
one-on-one meetings with venture capitalists to quick-pitch
sessions with angel investors, Biocom’s Capital Development
Committee implements programs that help attract, maintain and
cultivate growth throughout the Southern California life science
sector. Access to potential capital and resources are frequently
showcased by four distinct programs offered by Biocom: Partner
Days, Venture Days, Super Angel Days and the Annual Global Life
Science Partnering Conference.
Partner Days
Biocom’s Partner Days program, established in 2012, brings
buyers and sellers together to discuss potential partnerships,
licensing opportunities and/or M&A deals.
For Partner Days, the Biocom Capital Development Committee
invites representatives from a well-regarded pharmaceutical
CAPITAL
DEVELOPMENT
Capital Development Landscape: Southern
California’s Life Science Industry
By Oscar Rodarte,
Project Coordinator, Biocom

company to a day of one-on-one meetings with companies
interested in raising capital. Partner Days are held two to three
times per year.
Venture Days
Biocom Venture Days are designed to connect member companies
to Venture Capitalists from around the US. Each event, organized
by the Biocom Capital Development Committee, features an
intimate group of esteemed VCs. They hold one-on-one meetings
with pre-selected companies, based on pre-determined investment
criteria. Venture Days are held two to three times per year.
Super Angel Days
Biocom’s Super Angel Days is a program designed to offer serial
investors, or Super Angels, the opportunity to help fund innovation
and potentially add companies to their portfolio. Selected
companies are given the opportunity to “Quick Pitch” (3-minute
pitch) their company or idea to each Angel. Super Angel Days are
held once annually.
Global Life Science Partnering Conference
Biocom’s annual Global Life Science Partnering Conference
is an exclusive networking forum that bring together leading
deal makers, senior executives, VCs, emerging companies and
business development professionals from leading biotech and
pharmaceutical companies in one of the largest life science hubs
in the world, San Diego. The conference consists of relevant panel
discussions, one-on-one meetings, start-up company presentations,
and various networking opportunities. Please join us in 2017 for
the 7th Annual Global Life Science Partnering Conference on
March 1st and 2nd.
Future Direction
The life science industry in California, like the rest of the nation,
is characterized by economic uncertainty, marketplace volatility,
pricing pressures and increased demand for innovation. As
companies grow and build their pipelines, this expansion requires
fresh capital and viable funding opportunities.
Biocom accelerates life science success through its robust and
member-focused capital development programs, which continue
to attract investment dollars to California. With the thoughtful
leaders on the Capital Development Committee, we continue to
create innovative new programs and opportunities for collaboration
and investment. To learn more about our capital development
programs, please contact orodarte@biocom.org
Oscar Rodarte is a Project Coordinator with
a focus on Biocom’s Capital Development
Initiative.
Biotechnology innovation in areas such as genomics, microbiomics, pharmaceuticals, and
precision medicine is increasingly driven by informatics, requiring large scale computation
and storage.
SDSC’s array of computational infrastructure and storage, along with its cadre of experienced
scientists and engineers, is leveraged by local companies to provide support in next-generation
sequencing analyses, drug discovery, translational medicine, and other areas. We provide:
h Collaborative Research Opportunities
h HPC and Storage System Architecture and Design
h Big Data Expertise and Training
h Machine Learning and Predictive Analytics
h Bioinformatics Programming and Applications
h Data Science Training
Email or visit us online to see how we can help you reach your research objectives.
www.sdsc.edu/collaborate/ipp.html | ipp@sdsc.edu
A National Leader in High-Performance Computing & Big Data
Partnering with local biotech companies to accelerate discovery

If you didn’t already know that it’s been a busy few months for
Biocom, the quantity and diversity of these headlines tell the story.
Here’s a quick scan of the articles that have recently appeared
in some of the top local and state-wide publications as Biocom’s
leaders get the word out about drug innovation, workforce
development, geographic expansion and other key issues that
matter to our members.
Read the brief excerpts here:
BIOCOM IN
THE NEWS
Biocom’s Making Headlines
September 26, 2016
Biocom Life Science Catalyst winners named
By Bradley Fikes
Biocom, the San Diego-based life science trade group, has
named 10 winners of its new Life Science Catalyst Awards.
Presented along with San Diego Venture Group, the awards
recognize rising stars in research, technology and business fields
who have made a lasting contribution to the region’s life science
industry before turning 40.
A committee of Biocom and San Diego Venture Group members
vetted each nominee, evaluating then on innovation, leadership,
vision and other factors. Biocom selected the winners.
Read more at: http://bit.ly/2eMOyFB
August 4, 2016
BioLabs Is Additional Plus for Local Biotech Scene
By Brittany Meiling
A new coworking space called BioLabs San Diego is launching
this fall, hoping to fill the gaps left in the city’s biotech startup
space.
The project is a joint venture involving San Diego’s life science
industry group BIOCOM and BioLabs, a Cambridge-based company
that opened similar coworking spaces in biotech hotspots across
the country, including North Carolina, New York, and the Boston
area.
Read more at: http://bit.ly/2ewsIre
July 25, 2016
Job Seekers Take Note: Challenges Faced by Life Science Employers
By Angela Rose
By all accounts, the California life science industry is flourishing
as one of the leading employers in the state, providing work for more
than 280,000 professionals from the entry-level to the c-suite.
Demand is outpacing supply, and job opportunities are plentiful—
though they aren’t always easy to land. BioSpace recently spoke
with executives from the California Life Sciences Institute (CLSI),
Biocom Institute and San Francisco Bay division of the Centers of
Excellence about the recruiting and hiring challenges facing the
state’s life science employers. Their responses were illuminating
and may contain information job seekers can put to use when
preparing for their next life science position.
Read more at: http://bit.ly/2ewhzqq
July 12, 2016
Op-Ed: Jumpstarting the Conversation: LA Must Harness Its Life
Science Potential
By Dina Lozofsky
Who would have guessed that Los Angeles’ life science industry
was percolating with so much energy?
Well, those of us in the trenches of LA life sciences know. But
based on the dearth of news coverage and overall conversation about
the area’s many biotech happenings, most people are unaware of
the abundance of new healthcare technologies and startup activity
happening right around them. Here are some insights gained from
the recent First Look LA event, the annual “sneak peek” investor
showcase of local startups and spinouts that span the life science
spectrum.
Read more at: http://bit.ly/2eMLFEy

SUPERANGEL DAY:
On Monday, October 24, Biocom held the 2nd Annual
Super Angel Day with participation from Richard Heyman,
Ph.D. (Board Member at ORIC Pharmaceuticals), Francois
Ferre, Ph.D. (Co-CEO at ALMA Life Sciences) and Sheila
Gujrathi, M.D. (former CMO at Receptos). 35 companies
participated in the event including a number of first
time entrepreneurs which demonstrates the on-going,
innovative spirit of the Biocom membership. Following
the three minute, quick pitch session, the Angels
were questioned about the quality of companies they
saw – they were ‘inspired’ and ‘excited’ by the passion
and science demonstrated during the event. BioRibbon
Health, Chrysalis Therapeutics and Notogen, Inc. were
identified as the companies they would like to have
longer meetings with. Congratulations to all companies
that participated in the event.
Representatives from Bristol-Myers Squibb will be in San Diego on December
13th to meet with representatives from local academic institutions, research
organizations, venture capital firms, and companies with programs and
technologies complementary to Bristol-Myers Squibb’s pipeline and capabilities.
BMS is Looking For Companies working in the following therapeutic areas:
• Immuno-Oncology/Oncology
• Clinical Collaborations in Oncology
• Immunoscience
• Cardiovascular Fibrosis
For more information on the program and how to participate please contact
Oscar Rodarte at orodarte@biocom.org.
MEMBERS INACTION
Bristol-Myers Squibb & Biocom Partner Day

Technology develops with time. From our trusted rotary wall
phone, to the latest iphone7, technology advances based on culture
and the wants and needs of a society. The
same is true in medicine. One of the first
wearable cardiac pacemakers, powered
by batteries, was born out of necessity
due to a mishap in the weather. Patients
with plug-in pacemakers needed a better
option to secure their safety during a
power outage. Now, almost 60 years
later the company that gave patients their
wireless freedom (Medtronic) received
FDA approval for the world’s smallest
pacemaker. Their technology is even more
groundbreaking, because of where it is implanted: inside the heart.
As the world continues to evolve and grow, whether in pop culture
or modern medicine, it’s no surprise that there is a Guinness World
Record for the fastest genetic diagnosis. The record was recently
achieved by successfully diagnosing critically ill newborns in just
under 26 hours. The best part of this story is that the record-holder
is Dr. Stephen Kingsmore, M.D., D.Sc., a San Diego resident who
was named president and CEO of Rady Children’s Institute for
Genomic Medicine at Rady Children’s Hospital one year ago.
Rady’s new facility will be the first in the world to fold genetic
testing into its everyday way of care for patients. The San Diego
Union Tribune, in an article about Kingsmore’s naming, noted that
prior to the opening of this facility, “the only patients who generally
have had access to whole-genome sequencing were those enrolled
in a research project or clinical trial that pays for the expensive
diagnostic work. However, with the help of a $120 million donation
from La Jolla philanthropists Ernest and Evelyn Rady, Kingsmore
said he believes the new institute will be able to change that reality.”
Another of Dr. Kingsmore’s successes is the 50-hour genome,
named by Time Magazine as one of the top 10 medical
breakthroughs in 2012. This process can screen for about 4,500
diseases know to be linked to single-gene mutations in the DNA
of babies. While many other medical tests have to be processed
one at a time, eliminating possible contributing factors with each
result, this method takes only two days to complete, and covers
the spectrum of genetic diseases all in one test, creating answers
rapidly to save lives. “We are proud to have Stephen Kingsmore
in San Diego bringing his vision for pediatric genomic medicine to
life and helping families affected by genetic disease in our region”
said Tristan Orpin, Executive Vice President, clinical genomics at
Illumina. Dr. Kingsmore continues to work closely with llumina,
collaborating with the teams there to develop
more advanced technologies to diagnose and
treat his tiny patients.
At Rady’s, Kingsmore plans to begin small by
offering the sequencing to many of the patients
admitted to the hospital’s neonatal intensive
care unit who have no clear diagnosis. To
begin, much of the testing will be conducted
under the research protocols approved as part
of a $6 million grant he received from the
National Institutes of Health. “We’re going
to start in the Rady NICU (neonatal intensive
care unit), but then we’ll be putting it into ... other Level 3 NICUs.
Then we move to the pediatric intensive care units and then to
outpatient clinics…It’s going to take a decade. But we believe there
are children who don’t need to suffer, and we’re going to fix that one
child at a time,” said Kingsmore in a September 2015 San Diego
Tribune article.
As we continue to hear San Diego described as “the genomics
capital of the world”, local players in the industry like Rady
Children’s Hospital, Edico Genome and Illumina, are not only
helping the city to hold this title, but are also making strides daily to
keep it for years to come. “You’ve got to have the right institution,
the right set of doctors, a lot of money and the right sort of societal
fabric. San Diego, I believe, is the only place in the world that has
this magical constellation to pull it off,” said Kingsmore (The San
Diego Tribune).
SAVE THE DATE: 2017 Biocom Institute Festival of Science &
Engineering March 4-12, 2017. Sponsorship opportunities now
available! Contact spagano@biocom.org for information.
Sara Pagano is the Managing Director of
the Biocom Institute Festival of Science &
Engineering
SCIENCE
FESTIVAL
STEM In The Community – The Future Is Now In
Pediatric Genomics!
By Sara Pagano,
Managing Director, Biocom Institute Festival of Science & Engineering

navigate
innovate
thrive
Nixon Peabody’s cross-disciplinary Life Sciences
team provides legal solutions to help you thrive in an
industry with a constantly shifting landscape.
We have a rich understanding of the dynamics regarding
business, regulation, and competition that affect pharmaceutical,
biotechnology, and medical device companies.
Our attorneys are at the forefront of industry trends and working
with companies at various phases in their lifecycle. We are often
— advising clients about new business models
— navigating health care and other regulations
— protecting and enforcing IP rights
— connecting with private equity and other capital
— establishing clinical research relationships
The Life Sciences ecosystem presents a vast number of exciting
opportunities. We position ourselves to be your trusted advisor
and partner to maximize your success.
nixonpeabody.com/life_sciences
@nixonpeabodyllp

+ NON-GMO PROCESS
+ INCREASED YIELDS
+ IMPROVED ECONOMICS
www.nucelis.com
ACCELERATED STRAIN
ADVANCEMENT PLATFORM
ASAP

BIOCOM’S 9THANNUAL DEVICEFEST CONFERENCE: CONGRATSTOABREOS BIOSCIENCES:
The 9th Annual DeviceFest Conference welcomed more than 200 attendees
and brought together leaders in the medical device, digital health and
diagnostic world. The conference was a full day of exploration of the latest
developments around reimbursement, regulatory, funding vehicles, and
design-driven innovation.
Those who spoke revealed the exciting times ahead for the industry,
including our featured speaker, Bakul Patel, Associate Center Director for
Digital Health, at the Center for Devices and Radiological Health (CDRH), at
the Food and Drug Administration (FDA). Bakul shared with us that 90% of
all of the world’s data has been generated over the last two years, which is
remarkable and advantageous for research, but also somewhat mind boggling.
Despite this massive influx of data, challenges abound: from the collection
and storing of data, to whether or not the data is actionable, to the protection
of data. Fortunately, events such as DeviceFest provide a forum for executives
to collaborate and discuss the tough lessons they have already learned,
allowing the industry as a whole to advance.
One of the most exciting portions of the day was saved for last, when five
innovative companies pitched their technologies to a group of world-class
leaders and investors. Entrepreneurs were given just five minutes to explain
why their technology was revolutionary and then were given on-the-spot-
critiques. Audience members and the investor panel of judges then grabbed
their mobile devices to vote for the winner.
We’d like to again congratulate presenter and winner, Bradley Messmer,
Ph.D., CEO & Founder of Abreos Biosciences, who was deemed the “hottest”
device company in Southern California and the winner of the Five in 5 in the
Hot Seat session for DeviceFest 2016!
More about the Winner of DeviceFest 2016: Abreos Biosciences is an early
stage biotech company pioneering assays for detection of biologic drugs using
its proprietary Veritope™
technology.
Abreos develops laboratory-based
and point-of-care assays that enable
personalized dosing and counterfeit
detection of these expensive drugs,
such as therapeutic monoclonal antibodies. The company’s reagents and
assays are customizable and can be developed for the detection of any
biologic drug in a variety of formats, including lateral flow and ELISA.
Thank you to our 2016 DeviceFest Conference sponsors for your continued
support of Biocom.
MEMBERS INACTION

MEMBERS INACTION
BREAKFAST MEETING ON EMERGING DISEASES,INCLUDING ZIKA:
Karen Midthun, Former Director, Center for Biologics
Evaluation and Research (CBER), at the FDA discussed
the U.S. response to emerging infectious diseases as
well as what we have learned from previous outbreaks,
the role of the U.S. government in funding and
approving countermeasures to emerging pandemics and
threats, the importance of public-private collaboration
and how the life science industry can better engage and
respond to existing and future outbreaks.

It can be difficult to navigate a world where qualities like experience, integrity
and a solid reputation are the exception. For our team they’re the rule.
We have a proven history of representing leading life sciences companies in
locating and negotiating facilities, creating visionary work places, increasing
facility delivery schedules, optimizing productivity and reducing operational costs
of existing facilities.
Team up with us to create an environment for research, collaboration and
decision-making that inspires your next big breakthrough.
Real estate partners
in the life sciences industry.
Inspiring environments
for inspired breakthroughs.
jll.com/sandiego . 858.410.1252
Chad Urie . Steve Holland . Grant Schoneman

BIOCOM PACANNUAL ELECTED OFFICIALS & CANDIDATES RECEPTION:
The Illumina campus provided a picturesque setting for this
year’s Biocom PAC Elected Officials and Candidates Reception.
Biocom members were able to chat with policy makers and
those about to be elected to office in a warm, relaxed setting
and educate them about the industry and the advances being
made. This year we were honored to be joined by a majority
of the San Diego delegations in both Congress and the State
Legislature. Our thanks to signature sponsor Genentech and
host sponsor Illumina for making the event possible and one of
our most successful PAC receptions ever.
MEMBERS INACTION

Iliana Pulido is 22 years old, lives in the City Heights area of San
Diego, and received her high school diploma in 2013 from Arroyo
Paseo Charter School. She started community college right after
high school but left partway through her first semester for family
reasons. She stalled in her career path. Over the next few years,
she heard about various career training opportunities, but it wasn’t
until the letter from the San Diego Housing Commission arrived
with information about the Introductory Life Science Experience
(ILSE) Program that Iliana’s interest in going back to school was
sparked.
ILSE is a 21-month pilot program that was launched in October,
2015. It provides a re-entry pathway into a STEM career in the life
sciences for young adults 18-24, who are not currently in school,
and who have substantial barriers to employment, education and
career pathway planning. Through one-on-one support, coursework
at Miramar College, work readiness training, and a paid internship,
participants receive focused assistance in taking the next steps
on their career paths to higher education and/or employment. The
first group of 13 students recently finished their internships.
Iliana was among the first group of students, and began an
upward trajectory. She successfully completed 150 hours of work
readiness, completed Introduction to the Lab courses at Miramar
College, received her ILSE training certificate, and went on to
complete a paid internship at Vertex Pharmaceuticals. Iliana’s
participation in the ILSE pilot program inspired her and helped her
set goals. She enrolled as a full time student at Miramar College
and in September, she secured a part time job on campus as an
Instructional Assistant. Recently we sat down with Iliana and
asked her a few questions:
Q: What were you doing before you started the ILSE program?
A: I was working at a retail store stocking merchandise. I worked
there for four months and prior to that I was babysitting.
Q: What were your career and educational goals prior to beginning
the ILSE program?
A: My main goal was to go back to school. I knew I wanted to do
something in the medical field but wasn’t sure what.
Q: How have those career and educational goals changed since you
started ILSE?
A: The ILSE program gave me confidence to go back to school. I’ve
started taking classes at Miramar College and have a job there as
an Instructional Assistant. I want to pursue a radiology technician
program. I want to help people.
Q: What is the most important thing you learned in ILSE and how
will it help you?
A: I learned a lot of things, but mainly it inspired me to go back
to school and taught me not give up. When I left school the first
time, I didn’t have any support or anyone to motivate me. Now I
have Rogelio and Karen, at Biocom. Whatever I need, I can talk
to them.
Q: What are your impressions of the courses at Miramar?
A:The ILSE coursework was pretty interesting. I was surprised at
the amount of information we learned in a short amount of time. I
really liked the hands-on work learning laboratory techniques.
Q: What are your impressions of your internship?
A: I was pretty surprised that I got an internship at a biotech
company. I never saw myself working there. I was nervous going
into the internship, especially when I realized I would be doing
buffers. My supervisor made me do buffers my first week and by
the end of the week I got the hang of it and was doing them on
my own.
The ILSE program is supported by Workforce Investment
and Opportunity Act funding through the San Diego Workforce
Partnership. Additional support from a Blasker Science &
Technology Grant provided for student tours of the campus of two
local universities.
The ILSE program is continually matching interns in exciting
roles within life science and other organizations and the placement
of our second group of students is currently underway. Thank
you to Abbiotec, Althea, BioLegend, BioNano Genomics, Inovio
Pharmaceuticals, Media Arts Center, Mirati Therapeutics, Molecular
Response, Nanomedical Diagnostics, Reuben H. Fleet Science
Center and Vertex Pharmaceuticals for opening your doors to ILSE
interns and accelerating the STEM career opportunities for San
Diego’s youth. More companies are providing these opportunities
every week and some may not have made the list before this issue
of LifeLines went to print but we would like to thank all companies
who have provided their support.
Liisa Bozinovic is the Executive Director
of the Biocom Institute and also heads
Biocom’s HR Initiative.
BIOCOM
INSTITUTE By Liisa Bozinovic,
Executive Director, Biocom Institute
Pilot Program Helps Student Take Off

Scientist CEO
MBA | MFIN | MSBA | Ph.D. | ExecEd
To see more stories:
rady.ucsd.edu/radymade
#RadyMade
“The Rady School inspired me to ask, ‘Can things be
done a different way?’ The school’s Lab to Market and
the StartR Accelerator challenged my assumptions
and I learned how to build a business model based on
our customer’s needs. The Rady School has made a
huge impact on my career. I went from an individual
contributor to a leader and CEO of a startup that will
influence the life sciences industry.”
Julio de Unamuno IV, MBA ‘14
Founder and CEO
Lab Fellows, Inc.
I am RadyMade

The Biocom Purchasing Group continuously strives to emulate
the entrepreneurial spirit of the Biocom members we serve.
In 2016, strategic enhancements were made to our staff, our
statewide reach and to our core competencies in an effort to grow
concurrently with the speed and ingenuity of our membership.
This June, we oversaw the completion of a rigorous effort by
over 50 scientists, lab managers, supply chain specialists,
financial advisors and executive leaders within our membership.
An 18-month RFP process resulted in a Fisher Scientific Lab
Supply contract that awards Biocom members exclusive access to
unprecedented life science solutions.
This was the most robust and carefully-managed RFP process
our industry has ever seen. We leveraged the purchasing power
of over 800 members and relied on them to assemble a multi-
disciplinary team that resulted in a comprehensive and exclusive
contract that delivers competitive advantages for our members not
available anywhere else in the country.
Over the past year, we have added two staff to our contracts
team. This expansion allows us to strategically add more industry-
leading contracts that closely fit the evolving needs of California’s
life science sector. It also means we can perform more extensive
RFPs, develop more robust Advisory Committees, and expand our
formal member feedback systems.
In addition to our latest lab contract enhancement, 202 Biocom
members of the Beyond Benefits Trust, the only bona fide life
science health insurance trust in California, will now see a 1.4
percent DECREASE in their health insurance rates for the 2017
calendar year.
We understand the pain points of the life science industry in
California. We know that skyrocketing healthcare costs (with
an average increase of 10.4 percent annually) take their toll on
companies who might be forced to forego sustaining revenues for
years as they develop lifesaving medicines. Thanks to the Beyond
Benefits Trust and the positive claims history of our members, we
are seeing a decrease for over 6,800 covered lives in California; a
number that is growing weekly.
We’re also excited to announce that the threshold for California
life science companies eligible for the trust has been reduced from
a headcount of five to four employees. This is the first adjustment
in the trust’s five-year existence and a huge win for Biocom’s
smaller start-up companies looking to gain access to exclusive
state-wide health insurance benefits.
Our significant growth this past year with regard to member
engagement, contract offerings and targeted reach, has been fueled
in large part by our database capabilities. We continue to reinvest
a substantial share of our resources to create the infrastructure
necessary to build a network of life science companies that can
connect with each other to enable change, create life science
solutions and catapult California onto the global stage.
Examples of our continued focus on supporting members can
be found in Biocom’s new staff of five in our Los Angeles office
and our expanded services in the Bay Area. We are driving growth
and achieving breakthrough results across all regions of California
simultaneously, creating state-wide momentum.
Our strategic investments in people, our expanded geographic
reach, and our enhanced technologies have one thing in common:
they align with Biocom Purchasing Group’s vision of being the
most valued GPO in the world. And, they reflect Biocom’s vision of
being recognized by each member as the most valued organization
in strengthening and enhancing potential for life science success.
It is our world-class members who keep us at the forefront of
global purchasing programs, creating targeted solutions to ensure
bottom-line savings and cost-effective growth for all.
Stay tuned for future purchasing programs that will sustain
your bottom line, drive California’s life science industry, and
help all Biocom members recruit and retain the best talent.
If you are interested in joining our movement, volunteering
on a committee, attending one of our world-class events or
want to meet the incredible team here, please contact us at
PGSupport@biocom.org.
Rick Fultz oversees membership and
sponsorship efforts, business development
opportunities, and the Biocom Purchasing
Group.
PURCHASING
GROUP By Rick Fultz,
Managing Director, Biocom Purchasing Group
Accelerating Growth & Changing the Game

BIOCOM
TEAM
Tatiana Celebertti
Office Manager and Accounting Associate,
Los Angeles
tcelebertti@biocom.org
As the Office Manager and Accounting
Associate, Tatiana ensures daily
operations in the LA office are executed
smoothly and coordinates all aspects
of the day-to-day activities. She
holds a Masters in Leadership and
Organizational Studies and has
a positive and energetic personality
that tends to bring a smile to those
around her.
Mandy Abdi
Event Coordinator, San Diego
mabdi@biocom.org
Mandy, a San Diego native who has been
tech-ing it up in San Francisco for the
past three years, joined us in March of
2016 as our new PG Event Coordinator.
She is responsibile for developing a
strategic plan for sponsorship and event
opportunities for all of PG’s partners,
while managing the design, planning
and execution for events of all types and
sizes, across multiple industry segments.
Mandy holds a bachelor’s degree in
Business Management.
Maria Arrivello
Project Coordinator, San Diego
marriviello@biocom.org
As a recent biology graduate from the
University of South Carolina, Maria
is new to California, but not the life
science industry. We are using her
fresh perspective to streamline internal
communications, manage project
schedules, liaise PG Board engagement,
and help surpass PG goals with a
unified, cohesive and all-encompassing
approach.
Hanan Al-Hakim
Sr. Program Manager, Los Angeles
halhakim@biocom.org
As the Senior Program Manager at
Biocom’s Los Angeles office, Hanan is
responsible for all aspects of program-
related initiatives, including committee
and networking functions. She loves to
go to the beach, work out, cook and eat.
As a sports fan who was born and raised
in LA, Hanan is a die-hard Laker fan and
bleeds the purple and gold. Hanan is
a graduate of Cal State Northridge and
holds an MBA from Pepperdine.
We have had an exciting year and are
pleased to introduce you to some of
our new team members.
Our recently-opened Los Angeles office is now fully staffed and
operational, advancing on the mission to accelerate life science
success in specific and meaningful ways for members.
In San Diego, the addition of new employees represents
organic growth at the headquarters office.

BIOCOM TEAM
Matt D’Angelo
Contracts Project Coordinator, San Diego
mdangelo@biocom.org
We are excited to welcome Matt, a
San Diego native, to our team to assist
with our Member Advisory Committees
and Member Feedback Program. He
has proven that Chargers fans aren’t
extinct and he’ll be a tremendous help
to our contracts team by assisting with
overall project timelines, budgets and
communication. Matt earned a Bachelor
of Science degree from Sonoma State
University.
Morgan Harris
Data Analyst, San Diego
mharris@biocom.org
As Data Analyst, Morgan assists the
contract team with Market Research
efforts and translates collected data
on current and future contract areas
to support best practices and paths
forward in the development of Biocom
Purchasing Group’s contract portfolio.
As a San Diego native, Morgan enjoys
outdoor activities, sports and serving
his local community. Morgan holds
a Bachelor’s degree in International
Global Logistics and Supply Chain
Management.
Carol Knowles
Accounting Associate, San Diego
cknowles@biocom.org
Carol has joined our Accounting Team,
bringing extensive experience as a
professional accountant. When not
balancing the books, Carol can be
found in town cheering on the Chargers
with her family or visiting her sons and
granddaughter out of state.
Ben Li
Associate Director of Membership,
Los Angeles
bli@biocom.org
Ben, a Los Angeles native and UCLA
Bruin, is our latest addition to the Los
Angeles team following over a decade
of leading international sales for an
APAC device manufacture. He is equally
excited at the blossoming growth of
life science companies in Los Angeles
as he is about the young Lakers team,
and looks forward to both to become
prominent in their respective arenas.
Michelle Nemits
Director of Business Development,
San Francisco
mnemits@biocom.org
Michelle is Biocom Purchasing Group’s
latest hire, and has hit the ground
running in San Francisco. She has over
20 years of experience in the Bay Area
life sciences ecosystem; over ten of
which she spent with VWR as a Director
of Business Development before being
hired as the first employee at a life
science manufacturer and rising to CCO.
Michelle spends her free time coaching
her daughter’s volleyball team and looks
forward to expanding Biocom’s services
in Northern California.
Shannon Colette Lee
Senior Membership Coordinator, San Diego
slee@biocom.org
Shannon is the Senior Membership
Coordinator and is responsible for
supporting membership growth with
pipeline management of prospective
members from initial contact through
formal membership acceptance. In her
free time Shannon enjoys spending
time with her family and friends.
Shannon volunteers with the Scripps
Hospital and the Salk Institute and she
enjoys traveling and collecting wisdom
in unexpected places. Shannon is a
graduate of National University, San
Diego with a Bachelor of Arts in English.

BIOCOM TEAM
Ryan Palhidai
Business Development Manager,
Los Angeles
rpalhidai@biocom.org
Ryan joined us this summer as one of
our first hires in the new Biocom LA
office after a very successful stint at Life
Technologies, now Thermo Fisher. He
brings a wealth of industry knowledge
to the team at a time of critical growth,
and is a new dad, so we know his
drive to succeed is at an all-time high.
Ryan holds a Bachelor of Science in
Biochemistry and Cell Biology from
UCSD.
Lauren Panetta
Senior Communications and
Marketing Manager, San Diego
lpanetta@biocom.org
As the Senior Manager of Marketing &
Communications for Biocom, Lauren is
responsible for planning, developing, and
implementing Biocom’s marketing and
communication activities. She has an
unrelenting passion for cooking and any
sport that involves being in or around
the ocean, including paddleboarding and
scuba diving with the world’s diverse
marine life. She is a graduate of Cal
Poly, San Luis Obispo with a Bachelor of
Science in Graphic Communication.
Oscar Rodarte
Project Coordinator, San Diego
orodarte@biocom.org
As a Project Coordinator, Oscar is
responsible for supporting all aspects of
the Capital Development Initiatives of
Biocom. Oscar is a graduate of UCSD
with a degree in Human Development,
and comes to Biocom from the
healthcare industry. In his free time,
he enjoys traveling and exploring new
cuisines.
Andrew Smith
System Administrator, San Diego
asmith@biocom.org
It’s not only at the Crossfit Gym that
Andrew is lifting heavily; he is also our
‘heavy lifter’ in IT support and Salesforce
administration here at Biocom. He will
be working internally and externally to
streamline communication, manage
onboarding processes and new feature
training as well as Salesforce reporting.
Andrew holds a Bachelor’s degree in
Business Administration from California
State University, San Marcos (CSUSM).
Joe Spirito
Program Director, San Diego
jspirito@biocom.org
As Program Director, Joe supports the
relationships between PG, its Suppliers
and key Biocom partners. That’s a
lot of work to be balancing with golf
and Chargers season tickets. He is
also responsible for the development
of strategy and tactical execution
in contract administration, member
education and business development
for our key partner organizations. Joe
holds an MBA from USC and a B.S. in
Business Management from CSUSM.
Angela Wieszchowski
Sponsorship Sales Coordinator, San Diego
awieszchowski@biocom.org
As Biocom’s Sales Support Coordinator,
Angela works directly with the Events
department. She is responsible for the
support of company wide sponsorship
growth as well as managing the
relationships with all sponsors. Angela
earned a Bachelor of Science degree in
Biology from Northern Illinois University.

BOARD OF DIRECTORS
COMMITTEE LEADERSHIP
BOARD OFFICERS AND EXECUTIVE COMMITTEE:
CHAIR: Theodore Schroeder, Zavante Therapeutics*
VICE CHAIR: Carin Canale-Theakston, Canale Communications*
CHAIR ELECT: Daniel Burgess*
VICE PRESIDENTAND GENERAL COUNSEL: Lisa Haile, J.D., Ph.D., DLA Piper*
VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young*
VICE PRESIDENT – INDUSTRY: Christophe Schilling, Ph.D., Genomatica, Inc.*
VICE PRESIDENTAND SECRETARY: Brent D. Jacobs, Cushman & Wakefield*
CHAIR EMERITUS: Magda Marquet, Ph.D., Althea*
PRESIDENT & CEO: Joe Panetta, Biocom*
Vincent Anido, Ph.D., Aerie Pharmaceuticals
Steven Bartz, Ph.D., Merck & Company
Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo
Michael Brown, Stradling Yocca Carlson & Rauth
Sandra Brown, Ph.D., UCSD
Terrance J. Bruggeman, Avenzoar Pharmaceuticals, Inc.
Bruno Buisson, Ph.D., Neuroservice
Carol Cox, NuVasive
Charles Dadswell, Illumina*
John M. Dunn, Vital Therapies
David Enloe, Althea CMO
Stephen Ferruolo, J.D., Ph.D., USD School of Law*
Oliver Fetzer, Ph.D., Synthetic Genomics
M. Wainwright Fishburn, Jr., Cooley LLP*
Don Fitzgerald, Genentech
Jack Florio
Gregory Fond, Sanofi
Gregory Frost, F1 Oncology
Carol Gallagher
Wolfgang Glaesner, Ph.D., Eli Lilly & Company
Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati
Richard Heyman, Ph.D., Metacrine
Guy J. Iannuzzi, Mentus
Gerald Joyce, M.D., Ph.D., Genomics Institute of the Novartis Research Foundation
David Kabakoff, Ph.D., Sofinnova Ventures
Katherine Kantardjieff, Ph.D., California State University San Marcos
Paul Laikind, Ph.D., ViaCyte
Jacob Levin, Ph.D., UC Irvine
James Levine, Sapphire Energy*
Jack Lief, BioRegenerative Sciences, Inc.*
James Mackay, Ph.D, Ardea Biosciences
Damien McDevitt, Ph.D., GlaxoSmithKline
Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.*
Tracy Murphy*
Perry Nisen, M.D., Ph.D., Sanford-Burnham Prebys Medical Discovery Institute
Steven Pacelli, Dexcom
Richard Pascoe, Apricus Biosciences*
Kenneth Polin, Jones Day
Trindl Reeves, Barney & Barney LLC*
Dan Ryan, Alexandria Real Estate Equities
Camille Saltman, Malama Composites, Inc.
Dean Samsvick, KPMG
James Schaeffer, Ph.D., Calibr*
Timothy Scott, Pharmatek*
Bhasker Shetty, Ph.D., Pfizer La Jolla
Larry Stambaugh, Kalos Therapeutics*
Mark Stevenson, Thermo Fisher Scientific*
Tsuneo Takahashi, NF Corporation
David Weitz, Takeda California
Kenneth Weixel, Deloitte & Touche, LLP
Stephen Welter, San Diego State University
Tom West, Hologic
Matthew Williams, AbbVie
Scott N. Wolfe, Latham & Watkins
LIFE DIRECTOR:
Kennon W. Baldwin, Ferguson Pape Baldwin Architects*
David Hale, Hale BioPharma Ventures*
Brent D. Jacobs, Cushman & Wakefield*
Magda Marquet, Ph.D., Althea*
Tina Nova, Ph.D., Molecular Stethoscope
Biocom Board Members-Ex-Officio:
Mark Cafferty, San Diego Regional Economic Development Corporation
Peter Callstrom, San Diego Workforce Partnership
Sunita Cooke, Ph.D., Mira Costa College
Scott Lippman, MD, Moores Cancer Center, UCSD
Greg McKee, CONNECT
Peter Preuss
Jerry Sanders, San Diego Regional Chamber of Commerce
David Webb, Ph.D., Scripps Research Institute
*Executive Committee Member
Big Data
Larry Smarr, Cal(IT)2
Biocom Institute Board Committee*
Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc.
Capital Development Committee*
Carin Canale-Theakston, Canale Communications
David Kabakoff, Ph.D., Sofinnova Ventures
CRO Committee
Timothy Scott, Pharmatek
Environmental, Health and Safety Committee
Cliff Hanna
Dan Shiel, Pfizer La Jolla
Facilities Committee
Andy Darragh, Ferguson Pape Baldwin Architects
Brent D. Jacobs, Cushman & Wakefield
FDA Committee
David Enloe, Althea CMO
Michele Yelmene
Intellectual Property and Patent Law Committee
Daniel Hart, Knobbe Martens Olson & Bear LLP
Michael Mueller, Conatus Pharmaceuticals
International Committee
Kenneth Polin, Jones Day
Legislative Committee
Richard Ledford
April Grant, Sunovion Pharmaceuticals
Medical Device Committee
Mike Oliver, Spectra Science
Joleen Schultz, Rady School of Management, UCSD
Digital Health Committee
Apurv Kamath, Dexcom
Public Policy Oversight Committee*
Larry Stambaugh, Kalos Therapeutics
Paul Laikind, ViaCyte
Purchasing Board Committee*
Jack Lief, BioRegenerative Sciences, Inc.
Veterans Committee
Josh Vosovic, Accenture Accelerated RD
*Board Level Committees

PREMIUM
AbbVie
Airgas
Aldevron
Alexandria Real Estate Equities
Althea
Bayer
Barney & Barney
Biogen
Biomed Realty Trust
Biospace
BP Biosciences Center
Bridge Bank
California Manufacturing
Technology Consulting
Canale Communications
Celgene
COI Pharmaceuticals
Conatus Pharmaceuticals
Cooley LLP
Deloitte
DLA Piper
Dowling & Yahnke
Eli Lilly
Ernst & Young
Ferring Research Institute
Fisher Scientific
GE Healthcare Life Sciences
Genoptix
Hologic
Illumina
J-Labs
Jones Day
Kilroy Realty*
KPBS
KPMG
Latham & Watkins
Mentus
Merck Research Laboratories
Mesa Biotech
Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo
Nixon Peabody*
Novo Nordisk
NuVasive
Office Depot
Pfizer
Prometheus Laboratories
PwC
Thermo Fisher Scientific
Unisource Solutions
VWR International
Wilson Sonsini Goodrich & Rosati
BIOTECH
3-V Biosciences
Abbott Laboratories
Abgent
Abide Therapeutics
Abilita Bio*
Abreos Biosciences*
Abwiz Bio
ACADIA Pharmaceuticals
Acea Biosciences*
Actavalon*
ActivX Biosciences
Accugent Laboratories
Adigica Health*
Advanced BioMatrix
Advanced Targeting Systems
Advanced Tissue Scientific*
Aerie Pharmaceuticals
Agena Bioscience
Aimmune Therapeutics
Alector*
Allakos
AM Chemicals
Ambryx Biotechnology
Amgen
Amicrobe
AmpliPhi Biosciences
Amplyx Pharmaceuticals
Amyris
Amgiocrine Bioscience
Animantis
AnaptysBio
Animal Cell Therapies
Ansun Biopharma
Antiva Biosciences*
Apricus Biosciences
Apros Therapeutics*
Aptose Biosciences
Aratome
Arcturus Therapeutics
Arcus Bioscience
Ardea Biosciences
Arena Pharmaceuticals
Aries Pharmaceuticals*
Armetheon
Arrayomics
Arytha Biosciences
Asahi Kasei Pharma
Astellas Pharma
aTyr Pharma
Avantgen
Avelas
Avenzoar Pharmaceuticals
Avidity Biosciences
Aviva Biosciences
Bachem Americas
Balance Therapeutics*
BASF
Beloteca
BioLegend
Biomatrica
Biomyx
BioNano Genomics
Bionomics
BioRegenerative Sciences
Bird Rock Bio
Biosortia Pharmaceuticals
BioSpyder Technologies
Biotheryx*
BioWa
Boehringer-Ingelheim
BP Biosciences Center
CalAsia Pharmaceuticals
CalciMedica
Caribou Biosciences*
Cell Applications
Cellics Therapeutics
Cellular Research*
Center for Aquaculture Technologies
CereDx*
Channel Medsystems
Chrysalis Therapeutics*
Chubu Technology Licensing Office
Cibus
Cidara Therapeutics
Circuit Therapeutics
Cirina*
Coda Therapeutics
Coherus Biosciences
Conju-Probe
Contract Biotics
Crinetics Pharmaceuticals
CureMatch*
Curtana Pharmaceuticals
CV Sciences
Cyprus Therapeutics
CytomX Therapeutics
Dart Neuroscience
Decoy Biosystems*
Definiens
DEL Biopharma*
Dermata Therapeutics
Diomics Corporation
DNA Link USA
DNAtrix
DSM Food Specialties
EA Pharma Co., Ltd
E&B Technologies
Edico Genome
eFFECTOR Therapeutics
Elcelyx Therapeutics
Electronic BioSciences
Emerald Therapeutics
eMolecules
Epeius Biotechnologies
Epitracker
Eton Bioscience
Evofem Biosciences
F1 Oncology*
Fabrus
Fate Therapeutics
FibroGen
Fluoresprobe Sciences*
Forge Therapeutics
Forty Seven
Galena Biopharma
Geltor*
Genelux Corporation
Genentech
Genlantis
Genoa Pharmaceuticals
Genomatica
Genovo Corporation
GenSignia Life Sciences
GigaGen
GlaxoSmithKline
Global Medical & Research
Technologies
GlyTech*
GWR Instruments
Halozyme Therapeutics
Harpoon Therapeutics*
Helix
Heron Therapeutics
Histogen
Horizon Pharma USA
Human Longevity
Huya Bioscience International
Ideaya Biosciences*
Immix Biopharma*
Imprimis Pharmaceuticals
Inception Sciences
Indi Molecular
Inhibrx
InnoPep
Innovative Cell Technologies
Innoviva
Innovus Pharmaceuticals
Inovio Pharmaceuticals
InSilixia
Integrated DNA Technologies
Intercept Pharmaceuticals
International Stem Cell
Intrexon Corporation
Intrinsic LifeSciences
Invetech
InvivoGen
Ionis Pharmaceuticals
IRBCo.
JSR Micro
Kalos Therapeutics
Kalyra Pharmaceuticals
Kindred Biosciences
Koltan Pharmaceuticals
Koniku*
Kura Oncology
Kyowa Hakko Kirin California
La Jolla Biologics
La Jolla Pharmaceutical Company
Ligand Pharmaceuticals
Laguna Pharmaceuticals
Leading Biosciences
Linkage Bioscience
Lion Biotechnologies
Lpath
Lumena Pharmaceuticals
MabVax Therapeutics
Malama Composites
MAPP Pharmaceuticals
Mast Therapeutics
MDRejuvena
MedGenome*
MatriSys Bioscience*
MEI Pharma
Meiji Seika Pharma
Memphis Meats*
Metacrine
Mirati Therapeutics
Molecular Assemblies*
Molecular Response
Molecular Stethoscope
Monsanto
MultiVir
Myokardia
Nagano Science USA
NantWorks*
Nautilus Environmental
Neothetics
NeuCyte*
NeuroGenetic Pharmaceuticals
NF Techno Commerce
Nitto Denko Technical
Novartis Pharmaceuticals
Novoron Bioscience
Novvi
Nucelis
Nurix
OBI Pharma USA
Ocera Therapeutics
Ohr Pharmaceutical
Omniox
Oncternal Therapeutics*
Optimum Therapeutics
Orexigen Therapeutics
Origami Therapeutics*
OrPro Therapeutics
Otonomy
Oxford Bio Therapeutics
Pacira Pharmaceuticals
Panmira Pharmaceuticals
Patara Pharma
Pathway Genomics
PersImmune
Pfenex
PharmAkea
Pliant Therapeutics
Polaris Group
Polynoma
PolyPeptide Group
Poseida Therapeutics
Predictive Biology
PrimeGen Biotech
Primordial Genetics
Principia Biopharma
Prognosys Biosciences
ProSci
QED Bioscience
Receptos Services
Regulus Therapeutics
REKA Health
Rempex Pharmaceuticals
Renova Therapeutics
Repertoire Genesis
Retro Virox
REVOLUTION Medicines
BIOCOM MEMBERSHIP
*NewMembersfromMay2016toOctober2016

MEDICAL DEVICE
DIAGNOSTIC
Acon Laboratories
Adagio Medical*
Aethlon Medical
Alphatec Spine
Alpha-Tec Systems*
AltheaDx
Amydis Diagnostics
Aptitude Medical Systems*
Applied Proteomics
Astute Medical
Axonics Modulation Technologies
Banyan Biomarkers
BeneChill
Berkley Lights*
Biocept
BioDx
BioFluidica*
Biological Dynamics
Biomerica
Biospacific
bioTheranostics
Bio Trace Medical
Breathe Technologies
Bruin Biometrics
Burl Concepts
Canary Health*
Cell Idx
CeloNova BioSciences
Ceterix
ChromaCode
Clarify Medical*
Click Diagnostics
Cliniqa Corporation
CombiMatrix
Compellon
Confirm Biosciences
Critical Diagnostics
CTK Biotech
CVAC Systems
Cytori Therapeutics
DCN Diagnostics
DermTech International
DexCom
Diadexus
Dorsa Vi USA
Elixir Medical Corporation
Ellipse Technologies
Emerge Diagnostics
Endologix
Enigma Diagnostics
Entra Health
Epic Sciences
Epitope Diagnostics
Fallbrook Engineering
FemCap
FP Complete
Fortimedix USA
GenomeDx Biosciences
GenWay Biotech
GIMDx
Glaukos Corporation
Glysens
Guided Delivery Systems*
Heart Metabolics USA
Hitachi Chemical Research Center
Ichor Medical Systems
Ignyta
ImpediMed
ImThera Medical
Inari Medical
Inceptus Medical
INOVA Diagnostics
Interpreta
Interventional Spine
Invivoscribe Technologies
Ionian Technologies
Ivantis
KFx Medical
Kurin*
Luminex Corporation*
CRO/CMO
3DT Holdings
Abbiotec
ABL
Absorption Systems
Accelagen
Accenture Accelerated RD
Acurian
Advin Biotech
Agility Clinical
Alkahest
Alliance Protein Laboratories
AM Biomedical
American Peptide Company
AnaBios
Annova Chem
Aptuit
Argonaut Manufacturing Services*
Atheln
Bavarian Nordic
Behavioral Pharma
Bend Research
BioAtla
BioAuxilium Research*
BioBlocks
Bioclinova*
BioDuro
Bio-Edge
Bioserv Corporation
BTS Research
CalChem Synthesis
Cassia
Cato Research
Champions Oncology
Charles River Laboratories
ChemDiv
ChemPartner
Cleave Biosciences
Clintec International
Crown Bioscience San Diego
Cytelligen
Davos Chemical
Diagnomics*
Drug Delivery Experts
eStudySite
Eurofins Advantar Laboratories
Evotec
Exon BioSystems
Explora BioLabs
Genea Biocells
Global Blood Therapeutics
GRAM Laboratories
GW Pharmaceuticals*
Hamamatsu Pharma Research
Hamari Chemical San Diego Research
Center
HD Biosciences
Huntingdon Life Sciences
IDEXX BioResearch
ImmunoActiva*
IMS Health
Integrium Clinical Research
inVentiv Health Clinical
IriSys
JadeBio
KaloBios Pharmaceuticals
Lucidant Polymers*
Mediconomics
MedSource
MI Bioresearch
MicroConstants
MPI Research
My Chem LLC
Naeja Pharmaceutical
Neuropore Therapies*
Neuroservice
Neuro-Sys
Nexus Biosciences
Norac*
Ora
Pacific Rim Pathology
PacificGMP
PharPoint Research
PharmaDirections
Pharmapace*
Pharmaron*
Pharmatek Laboratories
PrimaPharma
Profil Institute for Clinical Research
PSI CRO
Puracyp
Qoolabs
Quadrants Scientific
Reveal Biosciences
Rho
Robarts Clinical Trials
SAFC Pharma
SGS Life Sciences
Sherpa Clinical Packaging
Spaulding Clinical Research
STA Pharmaceuticals*
Starfish Medical
SureClinical
SynteractHCR
TCR Medical Corporation*
Therapeutics, Inc.
Tioga Research
Toxikon
Toyota Tsusho Corporation
Triligent International
Ultimate Labs
Vala Sciences*
VIRAPUR
Wax-It Histology Services
WuXi AppTec
Zensun USA
Zyagen
BIOCOM MEMBERSHIP
BIOTECH CONT.
Ribomed Biotechnologies
Ridgeline Engineering
RIFT Biotherapeutics
Ritter Pharmaceuticals*
Roche Applied Science
Rohto Pharmaceutical
Roswell Biotech
Salveo Dx
Sapphire Energy
Samumed
Samsara Sciences
Sanofi
Scilex Pharmaceuticals
Scripps Laboratories
Second Genome
Senior Scientific
Senomyx
Senté
Sentynl Therapeutic
Seragon Pharmaceuticals
SGB
SillaJen Biotherapeutics*
Silicon Biosystems
Solstice Biologics
SomaLogic
Sophiris Bio
Sorrento Therapeutics
SOVA Pharmaceuticals
Sparsha Pharma USA
StemCells
Stemedica Cell Technologies
StemImmune
StemoniX
StemProtein
Sunesis Pharmaceuticals
Sunovion Pharmaceuticals
Sutro Biopharma
Synthetic Genomics
Takeda Pharmaceuticals U.S.A.
Tanabe Research Laboratories
Tarere Therapeutics
Target Discovery
TEGA Therapeutics
Tempo Therapeutics*
Tenova Pharmaceuticals
Theravance
Thesan Pharmaceuticals
Tizona Therapeutics*
Tocagen
Tonbo Biosciences
TP Therapeutics
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Trethera Corporation*
Triphase Accelerator
Triton Health Nutrition
UCB
US Specialty Labs
Vantari Genetics
Vaxiion Therapeutics
Verdezyne
Verndari*
Vertex Pharmaceuticals
Vet-Stem
ViaCyte
Vical
Viking Therapeutics
Visionary Pharmaceuticals
Vital Therapies
Vividion Therapeutics*
Wellspring Biosciences
Wildcat Discovery Technologies
World Fusion US
Xcell Biosciences*
Xencor
Yokogawa Electric
Zavante Therapeutics
Zosano Pharma

LLWinter2016 (3)

Recommended

Recommended

More Related Content

Similar to LLWinter2016 (3)

Similar to LLWinter2016 (3) (20)

LLWinter2016 (3)